Frazor Titus Edmondson III Sells 4,369 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Frazor Titus Edmondson III sold 4,369 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total transaction of $156,803.41. Following the transaction, the insider now directly owns 27,217 shares of the company’s stock, valued at approximately $976,818.13. This represents a 13.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Frazor Titus Edmondson III also recently made the following trade(s):

• On Friday, February 28th, Frazor Titus Edmondson III sold 14,544 shares of Zai Lab stock. The stock was sold at an average price of $32.98, for a total value of $479,661.12.

Zai Lab Stock Performance

ZLAB stock opened at $31.77 on Friday. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $39.77. The stock has a market capitalization of $3.48 billion, a price-to-earnings ratio of -11.47 and a beta of 1.07. The stock’s fifty day moving average is $32.72 and its two-hundred day moving average is $28.77.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The firm had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 million. As a group, analysts predict that Zai Lab Limited will post -2.58 EPS for the current fiscal year.

Institutional Trading of Zai Lab

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in Zai Lab during the 4th quarter worth $29,000. Pictet Asset Management Holding SA bought a new stake in shares of Zai Lab during the fourth quarter valued at about $31,000. Barclays PLC lifted its holdings in Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after purchasing an additional 2,856 shares during the period. US Bancorp DE grew its position in Zai Lab by 1,671.9% in the 4th quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after buying an additional 5,534 shares in the last quarter. Finally, Jasper Ridge Partners L.P. acquired a new position in Zai Lab during the 4th quarter valued at about $210,000. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ZLAB. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a report on Thursday, March 27th. JPMorgan Chase & Co. increased their target price on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Scotiabank assumed coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target on the stock. Finally, Bank of America reaffirmed a “neutral” rating and set a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.